Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study

• Prif Awduron: Baltazar Nunes (Awdur), James Humphreys (Awdur), Nathalie Nicolay (Awdur), Toon Braeye (Awdur), Izaak Van Evercooren (Awdur), Christian Holm Hansen (Awdur), Ida Rask Moustsen-Helms (Awdur), Chiara Sacco (Awdur), Massimo Fabiani (Awdur), Jesús Castilla (Awdur), Iván Martínez-Baz (Awdur), Hinta Meijerink (Awdur), Ausenda Machado (Awdur), Patricia Soares (Awdur), Rickard Ljung (Awdur), Nicklas Pihlström (Awdur), Anthony Nardone (Awdur), Sabrina Bacci (Awdur), Susana Monge (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.Research design and methods We linked electronic health records to create historical cohorts in Belgium, D...